"10.1371_journal.ppat.1004128","plos pathogens","2014-05-15T00:00:00Z","Fei Xiao; Isabel Fofana; Laura Heydmann; Heidi Barth; Eric Soulier; François Habersetzer; Michel Doffoël; Jens Bukh; Arvind H Patel; Mirjam B Zeisel; Thomas F Baumert","Inserm, U1110, Strasbourg, France; Université de Strasbourg, Strasbourg, France; Laboratoire de Virologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France; Pôle Hépato-digestif, Hôpitaux Universitaires de Strasbourg, Strasbourg, France; Copenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases and Clinical Research Centre, Hvidovre Hospital and Department of International Health, Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; MRC-University of Glasgow Centre for Virus Research, Glasgow, United Kingdom; Gastrointestinal Unit, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, United States of America","Conceived and designed the experiments: TFB FX IF. Performed the experiments: FX IF LH ES. Analyzed the data: FX IF LH HB ES FH MD MBZ TFB. Contributed reagents/materials/analysis tools: JB AHP. Wrote the paper: FX IF MBZ TFB.","I have read the journals policy and have the following conflicts: Inserm Transfer and the University of Strasbourg have filed patent applications on host-targeting entry inhibitors for prevention and treatment of HCV infection. Thomas F. Baumert serves as scientific advisor for Biotest and Vironexx. This does not alter our adherence to all PLOS policies on sharing data and materials.","2014","05","Fei Xiao","FX",11,TRUE,3,4,9,4,TRUE,TRUE,FALSE,0,NA,FALSE
